Skip to search formSkip to main contentSkip to account menu

BET Inhibitor GS-5829

Known as: GS 5829, GS-5829, GS5829 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
During the last decade, cancer research has significantly evolved into precision medicine and targeted therapies are now part of… 
2016
2016
The Combination of a BET Inhibitor (GS-5829) and a BTK Inhibitor (GS-4059) Potentiates DLBCL Cell Line Cell Death and Reduces Expression of MYC, IL-10, and IL-6 in Vitro
Introduction: GS-5829 is a potent and selective inhibitor of thebromodomain and extra-terminal (BET) family of proteins. BET… 
2016
2016
Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines
Introduction: GS-5829 is a potent and selective inhibitor of the bromodomain and extra-terminal (BET) family of proteins. BET… 
2016
2016
Evaluation of Idelalisib with B-Cell Receptor or Orthogonal Pathway Inhibitors in Diffuse Large B-Cell Lymphoma Cell Lines in Vitro and In Vivo
Background: Idelalisib, a selective oral inhibitor of PI3Kd, is approved for the treatment of chronic lymphocytic leukemia (CLL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)